The results of research on the Merck pill against Covid-19 are encouraging

0

Merck Sharp & Dohme pill in collaboration with Ridgeback Biotherapeutics against Covid-19 to be tested by European Medicines Agency (Coreper)

The Organization in announcement told him: “Following the EMA’s interim recommendations in support of national authorities that may decide to early use Lagevrio (molnupiravir) prior to marketing authorization, the more data from Lagevrio’s main study».

Research on Merck Lagevrio Pill Based 762 people showed that this pill reduced the risk of hospitalization or death in people with COVID-19 who were at higher risk of serious illness than 14.1% in the placebo group (placebo) in 7.3% in the Lagevrio team. The study did not include people who had been vaccinated.

Respectively, results based 1,408 people, show that the Lagevrio reduced the risk of hospitalization or death in people with COVID-19 who were at higher risk of serious illness than 9.7% in the placebo group in 6.8% in the Lagevrio team.

Coreper will examine the above data in order to issue an application marketing authorization of the drug.

See also: Micron mutation: Reduces the effectiveness of vaccines – Booster doses are absolutely necessary

Leave A Reply

Your email address will not be published.